Fibrosis Assay Services

Overview

There have been significant, recent advancements in fibrotic disease therapeutics development, including clinical progression of small molecules and biologics, and more novel modalities and delivery methods, such as siRNA nanoparticles. Fibrosis-targeted therapeutics require robust, high-content, cell-based assays to evaluate efficacy and mechanism of action, but the history of failure of anti-fibrotic therapeutic agents at clinical stages of development suggest that current assays are inadequate for these purposes. These failures may largely be due to the need for a physiologically relevant in vitro model, as most development has been performed in non-human or immortalized cells. To reduce this risk, we use primary human cells to better recapitulate the environment from which fibrotic pathologies originate.